Organon & Co.

For the period ended Mar 31, 2025. Filed May 2, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 2, 2025

OGN$13.89+0.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(Unaudited, $ in millions except shares in thousands and per share amounts)

	March 31, 2025	December 31, 2024
Assets
Current Assets:
Cash and cash equivalents	$547	$675
Accounts receivable (net of allowance for doubtful accounts of $12 in 2025 and $14 in 2024)	1,457	1,358
Inventories (excludes inventories of $207 in 2025 and $215 in 2024 classified in Other assets)	1,362	1,321
Other current assets	1,005	994
Total Current Assets	4,371	4,348
Property, plant and equipment, net	1,197	1,168
Goodwill	4,680	4,680
Intangibles, net	1,417	1,414
Other assets	1,491	1,491
Total Assets	$13,156	$13,101
Liabilities and Equity
Current Liabilities:
Current portion of long-term debt	$20	$20
Trade accounts payable	1,006	1,153
Accrued and other current liabilities	1,413	1,411
Income taxes payable	176	134
Total Current Liabilities	2,615	2,718
Long-term debt	8,936	8,860
Deferred income taxes	69	74
Other noncurrent liabilities	994	977
Total Liabilities	12,614	12,629
Contingencies (Note 15)
Organon & Co. Stockholders’ Equity:
Common stock, $0.01 par valueAuthorized - 500,000Issued and outstanding - 257,950 in 2025 and 257,799 in 2024	3	3
Additional paid-in capital	130	108
Retained earnings	1,026	1,010
Accumulated other comprehensive loss	(617)	(649)
Total Stockholders’ Equity	542	472
Total Liabilities and Stockholders’ Equity	$13,156	$13,101

-5-

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.